Benralizumab is an interluken-5 receptor monoclonal antibody licensed for the treatment of severe eosinophilic asthma. It binds to the IL-5 receptor expressed on eosinophils and basophils, leading to apoptosis of these cells through cell‑mediated cytotoxicity and aims to reduce eosinophilic inflammation. Clinical trials showed a reduction in asthma exacerbation rates and maintenance oral corticosteroids (mOCS).
A recent study published in CHEST journal evaluated the real-world effectiveness of Benralizumab and any baseline characteristics associated with response to therapy.
Exacerbation history, mOCS dose, spirometry, Asthma Control Questionnaire (ACQ6) and mini-Asthma Quality of Life Questionnaire (mAQLQ) scores were recorded for 130 patients over 48 weeks of treatment.
Treatment response was defined as a reduction of ≥50% in annualised exacerbation rate (AER) or in mOCS. Super-response was defined as zero exacerbations and no mOCS for asthma.
There were clinically and statistically significant improvements in ACQ6, mAQLQ and FEV 1. Overall, 39% met the super-responder definition, and 86% the responder definition.
Reference:
Real World Effectiveness of Benralizumab in Severe Eosinophilic Asthma
Joanne E. Kavanagh, Andrew P. Hearn, Jaideep Dhariwal, Gráinne d’Ancona, Abdel Douiri, Cris Roxas, Mariana Fernandes, Linda Green, Louise Thomson, Alexandra M. Nanzer, Brian D. Kent, David J. Jackson. Published: August 31, 2020DOI:https://doi.org/10.1016/j.chest.2020.08.2083
